Statins but Not PCSK9 Inhibition Linked to Adverse Neurocognitive Effects
A drug-target Mendelian randomization (MR) analysis indicated adverse neurocognitive effects related to statins but not proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Data were from a combined sample of ∼740,000 participants in predominantly European ancestry-based genome-wide association cohort studies. There was a neutral cognitive profile related to genetic PCSK9 inhibition, […]